Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine

Rui Kitadai,Tatsunori Shimoi,Shu Yazaki,Hitomi Sumiyoshi Okuma, Mai Hoshino,Munehiro Ito,Ayumi Saito,Shosuke Kita,Yuki Kojima,Tadaaki Nishikawa, Kazuki Sudo,Emi Noguchi, Yasuhiro Fujiwara,Masayuki Yoshida,Kan Yonemori

Breast Cancer（2024）

Cited 0|Views0

No score

Abstract

HER2-low populations constitute a heterogeneous group, and the cytotoxic anticancer agent efficacy based on HER2 status remains unclear. This study evaluated the clinicopathological features and outcomes of patients with advanced breast cancer showing HER2-low expression treated with eribulin or capecitabine, two treatment options after anthracycline and taxane treatment. We retrospectively evaluated patients who were treated with eribulin or capecitabine between 2011 and 2015. HER2 status was evaluated according to the ASCO/CAP guidelines. No significant difference was observed in overall survival (OS; eribulin: hazard ratio [HR], 0.66; 95

Translated text

Key words

HER2-low,Advanced breast cancer,Eribulin,Capecitabine,Overall survival

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined